The Australian Competition and Consumer Commission (ACCC) has cleared Allianz Partners to proceed with its acquisition of a large portion of nib Group’s Australian and New Zealand travel insurance portfolio – closing the regulatory chapter on a divestment that has removed one of Australia’s largest health insurers from travel insurance underwriting entirely.
The clearance is notable for reasons beyond the deal itself. Australia’s mandatory merger control regime came into effect on January 1, 2026, replacing the previous voluntary notification system and requiring businesses to obtain ACCC approval before completing qualifying acquisitions. This transaction is among the first significant insurance sector deals cleared under that framework. According to the ACCC's acquisitions register, AWP Australia Pty Ltd, trading as Allianz Global Assistance, is the acquiring entity. AWP issues and manages travel insurance as agent for Allianz Australia Insurance Limited, which underwrites the policies. Prior to the transaction, nib distributed travel insurance products under brands including nib Travel that were underwritten by Pacific International Insurance Pty Ltd.
The ACCC’s specific competition analysis for this transaction has not yet been published. However, the unconditional clearance is notable given the broader market context. IBISWorld describes the Australian travel insurance market as moderately concentrated. While the ACCC’s detailed reasoning is not yet public, its decision to clear the transaction without conditions suggests it did not identify competition concerns sufficient to block or condition the acquisition.
The transaction, first announced on June 5, 2026, includes the acquisition of the Travel Insurance Direct (TID) brand, a large portion of nib’s established travel insurance intermediary relationships in Australia, and a 20-year white-label distribution agreement with nib Group in both Australia and New Zealand. The sale price is up to $50 million, comprising approximately $30 million receivable on completion and $20 million subject to certain conditions being met over the first 12 months following completion. nib will also receive ongoing distribution commissions separate from the headline sale figure.
Chris McHugh (pictured), chief executive officer of Allianz Partners Australia, said the clearance was a key milestone. “Receiving regulatory approval is an important milestone that brings us closer to welcoming nib’s travel insurance customers and partners into the Allianz Partners family. We look forward to delivering world-class insurance and assistance products to even more Australian and New Zealand travellers,” McHugh said.
The ACCC approval marks the conclusion of nib’s complete exit from travel insurance underwriting. The sale follows the announcement in May 2025 that nib would review its travel insurance business, including three travel insurance brands: World Nomads, Travel Insurance Direct, and nib Travel. Nib’s retreat from the space reflects a broader reallocation of capital. The company reported a 25% drop in group profit to $105.8 million for the first half of FY25, citing subdued margins in its Australian health insurance segment and a swing to loss in its New Zealand operations. The firm’s New Zealand arm reported a NZ$10.9 million deficit, weighed down by claims inflation and operational costs. In fiscal year 2025, nib Travel contributed $6.7 million to nib Group’s underlying operating profit of $239.2 million, representing less than 3% of the group’s total underlying operating profit.
In February 2026, nib announced the sale of World Nomads to International Medical Group, a wholly owned subsidiary of SiriusPoint, for cash consideration of $67.5 million. The Allianz Partners deal completes the exit. Combined, the two transactions represent up to $117.5 million in disclosed proceeds from nib’s full withdrawal from travel insurance underwriting. nib managing director and chief executive officer Ed Close framed the move as a deliberate portfolio simplification. “The transition simplifies our portfolio and allows us to focus our capital and capability where we see the strongest long-term value,” Close said. Close had previously signalled to investors a more disciplined capital allocation strategy, indicating an intention to focus on more resilient verticals such as international health and NDIS-linked businesses.
The transaction brings a material change in counterparty for insurance intermediaries currently distributing nib travel insurance. The acquisition covers a large portion of nib’s established intermediary relationships in Australia, meaning brokers and aggregators will transition to Allianz Partners as their underwriting counterpart. The shift also changes the underwriter on affected policies from Pacific International Insurance to Allianz Australia Insurance Limited. Intermediaries with binding authorities, referral arrangements, or distribution agreements tied to nib should review those arrangements before the transition completes. No specific transition date or process has been publicly disclosed.
The market size of the travel insurance industry in Australia is $1.4 billion in 2026, with 43 businesses operating in the sector. The acquisition expands the footprint of the market’s existing largest underwriter at a time when the sector is consolidating. Based on Coverager data, the transaction is among the largest travel insurance deals with a disclosed value in recent years, second only to nib’s own $67.5 million World Nomads divestment earlier in 2026. The parties are working toward completion, with no closing date announced.
